Methylnaltrexone bromide

ApprovedCompleted

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Opioid-Induced Constipation

Conditions

Opioid-Induced Constipation

Trial Timeline

Jul 1, 2008 → May 1, 2013

NCT ID

NCT00672139

About Methylnaltrexone bromide

Methylnaltrexone bromide is a approved stage product being developed by Bausch Health for Opioid-Induced Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT00672139. Target conditions include Opioid-Induced Constipation.

What happened to similar drugs?

3 of 20 similar drugs in Opioid-Induced Constipation were approved

Approved (3) Terminated (8) Active (10)

✅Naldemedine + PlaceboShionogiApproved

✅methylnaltrexone + placeboBausch HealthApproved

✅Methylnaltrexone + PlaceboBausch HealthApproved

🔄Naldemedine + PlaceboShionogiPhase 3

❌NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01366326	Phase 1	Completed	Jul 1, 2010	Aug 1, 2010	Healthy Adult Subjects
NCT00672139	Approved	Completed	Jul 1, 2008	May 1, 2013	Opioid-Induced Constipation

Competing Products

20 competing products in Opioid-Induced Constipation

See all competitors

Product	Company	Stage	Hype Score
Naldemedine + Placebo	Shionogi	Phase 3	40
Naldemedine + Placebo	Shionogi	Approved	50
Naldemedine	Shionogi	Phase 1/2	39
Naldemedine + Placebo	Shionogi	Phase 3	40
Placebo + Naldemedine	Shionogi	Phase 2	35
Naldemedine + Placebo	Shionogi	Phase 3	40
Naloxegol	Kyowa Kirin	Pre-clinical	26
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	32
NKTR-118 + Usual care	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
Naloxegol + Placebo Oral Capsule	AstraZeneca	Phase 2	27
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Methylnaltrexone bromide + Placebo	Pfizer	Phase 2	35